Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T03410
(Former ID: TTDI02125)
|
|||||
| Target Name |
Mycobacterium Membrane protein mmpL3 (MycB mmpL3)
|
|||||
| Synonyms |
Trehalose monomycolate exporter MmpL3; TMM exporter MmpL3
Click to Show/Hide
|
|||||
| Gene Name |
MycB mmpL3
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Bacterial infection [ICD-11: 1A00-1C4Z] | |||||
| 2 | HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] | |||||
| 3 | Asthma [ICD-11: CA23] | |||||
| Function |
Transports trehalose monomycolate (TMM) across the inner membrane. Could also be part of a heme-iron acquisition system.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| Sequence |
MFAWWGRTVYRYRFIVIGVMVALCLGGGVFGLSLGKHVTQSGFYDDGSQSVQASVLGDQV
YGRDRSGHIVAIFQAPAGKTVDDPAWSKKVVDELNRFQQDHPDQVLGWAGYLRASQATGM ATADKKYTFVSIPLKGDDDDTILNNYKAIAPDLQRLDGGTVKLAGLQPVAEALTGTIATD QRRMEVLALPLVAVVLFFVFGGVIAAGLPVMVGGLCIAGALGIMRFLAIFGPVHYFAQPV VSLIGLGIAIDYGLFIVSRFREEIAEGYDTETAVRRTVITAGRTVTFSAVLIVASAIGLL LFPQGFLKSLTYATIASVMLSAILSITVLPACLGILGKHVDALGVRTLFRVPFLANWKIS AAYLNWLADRLQRTKTREEVEAGFWGKLVNRVMKRPVLFAAPIVIIMILLIIPVGKLSLG GISEKYLPPTNSVRQAQEEFDKLFPGYRTNPLTLVIQTSNHQPVTDAQIADIRSKAMAIG GFIEPDNDPANMWQERAYAVGASKDPSVRVLQNGLINPADASKKLTELRAITPPKGITVL VGGTPALELDSIHGLFAKMPLMVVILLTTTIVLMFLAFGSVVLPIKATLMSALTLGSTMG ILTWIFVDGHFSKWLNFTPTPLTAPVIGLIIALVFGLSTDYEVFLVSRMVEARERGMSTQ EAIRIGTAATGRIITAAALIVAVVAGAFVFSDLVMMKYLAFGLMAALLLDATVVRMFLVP SVMKLLGDDCWWAPRWARRLQTRIGLGEIHLPDERKRPVSNGRPARPPVTAGLVAARAAG DPRPPHDPTHPLAESPRPARSSPASSPELTPALEATAAPAAPSGASTTRMQIGSSTEPPT TRLAAAGRSVQSPASTPPPTPTPPSAPSAGQTRAMPLAANRSTDAAGDPAEPTAALPIIR SDGDDSEAATEQLNARGTSDKTRQRRRGGGALSAQDLLRREGRL Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | SQ-109 | Drug Info | Phase 2 | Bacterial infection | [2], [3] | |
| 2 | BM-212 | Drug Info | Phase 1 | Asthma | [4] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | SQ-109 | Drug Info | [1] | |||
| 2 | BM-212 | Drug Info | [4] | |||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Lauryl Maltose Neopentyl Glycol | Ligand Info | |||||
| Structure Description | Cryo-EM structure of the mycolic acid transporter MmpL3 from M. tuberculosis | PDB:7NVH | ||||
| Method | Electron microscopy | Resolution | 3.00 Å | Mutation | No | [5] |
| PDB Sequence |
MFAWWGRTVY
10 RYRFIVIGVM20 VALCLGGGVF30 GLSLGKHVTQ40 SGFYDDGSQS50 VQASVLGDQV 60 YGRDRSGHIV70 AIFQAPAGKT80 VDDPAWSKKV90 VDELNRFQQD100 HPDQVLGWAG 110 YLRASQATGM120 ATADKKYTFV130 SIPLKGDDDD140 TILNNYKAIA150 PDLQRLDGGT 160 VKLAGLQPVA170 EALTGTIATD180 QRRMEVLALP190 LVAVVLFFVF200 GGVIAAGLPV 210 MVGGLCIAGA220 LGIMRFLAIF230 GPVHYFAQPV240 VSLIGLGIAI250 DYGLFIVSRF 260 REEIAEGYDT270 ETAVRRTVIT280 AGRTVTFSAV290 LIVASAIGLL300 LFPQGFLKSL 310 TYATIASVML320 SAILSITVLP330 ACLGILGKHV340 DAEEVEAGFW385 GKLVNRVMKR 395 PVLFAAPIVI405 IMILLIIPVG415 KLSLGGISEK425 YLPPTNSVRQ435 AQEEFDKLFP 445 GYRTNPLTLV455 IQTSNHQPVT465 DAQIADIRSK475 AMAIGGFIEP485 DNDPANMWQE 495 RAYAVGASKD505 PSVRVLQNGL515 INPADASKKL525 TELRAITPPK535 GITVLVGGTP 545 ALELDSIHGL555 FAKMPLMVVI565 LLTTTIVLMF575 LAFGSVVLPI585 KATLMSALTL 595 GSTMGILTWI605 FVDGHFSKWL615 NFTPTPLTAP625 VIGLIIALVF635 GLSTDYEVFL 645 VSRMVEARER655 GMSTQEAIRI665 GTAATGRIIT675 AAALIVAVVA685 GAFVFSDLVM 695 MKYLAFGLMA705 ALLLDATVVR715 MFLVPSVMKL725 LGDDCWWAPR735 WARRLQTRIG 745 LGEIHLP
|
|||||
|
|
GLN40
3.591
SER41
3.530
GLY42
4.298
PHE43
4.718
TYR44
3.646
ASP46
4.082
VAL51
3.692
SER54
3.207
VAL55
3.962
ASP58
3.477
GLY67
3.753
VAL70
4.407
ASP139
3.345
GLY165
3.655
LEU166
3.657
VAL169
3.562
ALA170
4.681
LEU173
3.700
THR174
3.650
|
|||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
| Protein Name | Pfam ID | Percentage of Identity (%) | E value |
|---|---|---|---|
| Otogelin (OTOG) | 30.818 (49/159) | 2.42E-04 |
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1797-809. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7997). | |||||
| REF 3 | ClinicalTrials.gov (NCT01218217) Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB. U.S. National Institutes of Health. | |||||
| REF 4 | MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother. 2012 Jan;56(1):324-31. | |||||
| REF 5 | Cryo-EM structure and resistance landscape of M.?tuberculosis MmpL3: An emergent therapeutic target. Structure. 2021 Oct 7;29(10):1182-1191.e4. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.